Resistance to third generation cephalosporins and carbapenems in Gram-negative bacteria is chiefly 22 mediated by beta-lactamases including ESBL, AmpC and carbapenemase enzymes. Routine phenotypic 23 detection methods do not provide timely results, and there is a lack of comprehensive molecular panels 24 covering all important markers. 25 An ESBL/carbapenemase HRM assay (SHV, TEM, CTX-M ESBLs, and NDM, IMP, KPC, VIM and OXA-48-like 26 carbapenemases) and an AmpC HRM assay (16S rDNA control, FOX, MOX, ACC, EBC, CIT and DHA) were 27 designed, and evaluated on 111 Gram-negative isolates with mixed resistance patterns. 28 The sensitivity for carbapenemase, ESBL and AmpC genes was 96.7% (95%CI:82.8-99.9%), 93.6% 29 (95%CI:85.7-97.9%) and 93.8% (95%CI:82.8-98.7%), respectively with a specificity of 100% (95%CI:95.6-30 100%), 93.9% (95%CI:79.8-99.3%) and 93.7% (95%CI:84.5-98.2%). 31 The HRM assays enable the simultaneous detection of the fourteen most important ESBL, 32 carbapenemase and AmpC genes and could be used as a molecular surveillance tool or to hasten 33 detection of AMR for treatment management. 34 35 36
Introduction 37
The widespread resistance to first-and second-line antibiotics is one of the greatest challenges for the 38 management of patients infected with Gram-negative bacteria, such as Escherichia coli and Klebsiella 39 pneumoniae 1 . The spread of Antimicrobial resistance (AMR) is facilitated by the organisms ability to 40 maintain and transmit plasmids and other mobile elements containing resistance genes, such as those 41 encoding beta-lactamases 2 . 42
Resistance to 3 rd generation cephalosporins is frequently caused by extended spectrum beta-lactamase 43 (ESBL) or AmpC genes, which are frequently mediated by plasmids 3 . There are three main classes of 44 ESBL; the TEM, SHV and CTX-M types, with the latter being the most prevalent class in the United 45 Kingdom, and worldwide 4,5 . 46
Infection with ESBL producers increases the length of hospitalization and mortality 6 and accounts for 47 approximately 10% of E. coli isolates from serious blood stream infections in the UK 5,7 . Reports from 48 global surveillance networks have shown that ~15% of E. coli isolates in hospitals are ESBL producers, 49 with a greater prevalence ranging from 20% to 60% in China and Southeastern Asian countries 8 . AmpC 50 genes are chromosomally carried by some members of the Enterobacteriaceae, including Enterobacter 51 spp and Citrobacter freundii complex, and confer resistance to third generation cephalosporins and 52 cephamycin, and plasmid mediated AmpC genes have enabled their spread throughout the 53 Enterobacteriaceae 9 . Acquired AmpC production in the Enterobacteriaceae is less frequently 54 encountered than ESBL production, but is increasing 8 , notably in Southeast Asia where 12% of E. coli in 55 hospitals have plasmid-mediated AmpC genes 10 . 56
Resistance to carbapenems, which are used as second line drugs for cephalosporin resistance, is 57 becoming widespread. Carbapenemases include the enzymes VIM, IMP and NDM, KPC, and OXA 58 carbapenemases 11 . The prevalence of carbapenemase producers varies wildly worldwide, with <1% of 59 invasive K. pneumoniae in the UK carrying these genes, compared with 66.9% in Turkey 12 . The 60 treatment options for infections of carbapenemase-producing organisms are limited and associated with 61 poor clinical outcome 13 , a 2-fold increase in mortality 14 and higher treatment costs 15 . Determining 62 antimicrobial susceptibility is a key diagnostic component to increase the likelihood of treatment 63 success and to enable antimicrobial stewardship 16 . 64
The detection of resistance to third generation cephalosporins and carbapenems is usually established 65 by phenotypic tests such as the CLSI double disk potentiation method 17 , the Etest (Biomerieux, France) 66 18 and the modified Hodge test 19 . These methods provide key information on drug susceptibility 67 phenotype, but require two 24-hour incubation periods, one to isolate the organism and a further 68 incubation to establish the drug sensitivity profile. These steps usually take 48-96 hours with antibiotic 69 prescription initiated empirically, resulting in the unnecessary use of last resort antibiotics and an 70 increased risk of drug resistance 20 . Recently rapid diagnostic tests have been developed for testing 71 bacterial colonies, utilising antibody mediated capture of carbapenem or ESBL enzymes and providing a 72 visual read out within 15 minutes 21 . Rapid phenotypic tests based on the colormetric detection of 73 carbapenem hydrolysis are also commercially available, notably the Rapidec Carba NP 22 , which is 74 sensitive for the detection of most carbapenemases, but insensitive for detecting OXA-type enzymes 23 . 75
Molecular assays are also increasingly used to detect resistance markers 24 . The PCR detection of ESBL 76
and carbapenemase genes has a high correlation with phenotypic testing, and provides faster results 77 25, 26 . Molecular testing reduces the time needed to provide targeted therapy 27 . However, their use as 78 first line diagnostics has been limited because the high number of genes involved necessitates a high 79 degree of multiplexing. For example, a current PCR assay for ESBL alone requires 3 PCR reactions with 7 80 primer sets, due to their variation across three gene families 28 . Currently "sample to answer" tests are 81 available such as the GeneXpert CarbaR (Cepheid, US) and FilmArray Blood culture ID (BioFire, US) 82 assays, but their expense makes them difficult to use routinely, and often targeted at high risk sub-83 populations 29 . The panels are also not comprehensive, for example the FilmArray assay only includes 84 three resistance markers in its 27 targets, and so provides insufficient evidence to change antibiotic 85 therapy based on likely resistance 30 . 86
High resolution melt analysis (HRM) is an endpoint detection method that can be utilised for real time 87 PCR assays to distinguish reaction products based on their melting point. This technique has a greater 88 potential for multiplexing than probe based assays, as it is not limited by the number of channels 89 available in the qPCR system 31 . HRM assays have been designed for bacterial resistance genes, including 90 carbapenemases 32-34 , AmpCs 35 , OXA-48-like beta-lactamases 36 , chloramphenicol resistance 37 and 91 mutations in aac(6')-lb-cr 38 . However, current assays include a maximum of six targets, and multiple 92 tests are required to thoroughly detect resistance to a drug type. The assay is less costly to operate than 93 probe based approaches, due to the use of an intercalating dye rather than labelled oligonucleotides. 94
This report describes a two-tube HRM assay for the detection of 14 markers of cephalosporin and 95 carbapenem resistance, including the major carbapenemase, ESBL and plasmid mediated AmpC genes. 96
Methods 97

Assay development 98
Sequences for each target gene were accessed from GenBank. A minimum of 30 sequences were 99 retrieved for each gene, and care was taken to include a wide coverage of genotypes alongside the 100 reference sequence from the Bacterial Antimicrobial Resistance Reference Gene Database (GenBank 101 Accession PRJNA313047). Sequences of each gene were aligned using Clustal X in MEGA 7, and areas of 102 conservation marked as potential primer binding sites. Primers were designed using Primer3, with a 103 distinct amplicon Tm defined for each target, to enable their differentiation by HRM. A minimum 104 difference of 1 o C Tm was selected for each amplicon. The final Tm prediction was obtained using the 105 nearest neighbor calculation on OligoCalc. Primer specificity was checked using Primer BLAST, against 106 the entire non-redundant database. Primers for detecting the carbapenemases KPC, VIM, OXA-48, NDM, 107 and IMP were multiplexed with primers for the three main ESBL groups CTX-M, SHV-like and TEM-like in 108 the ESBL/Carbapenemase assay. 109
The AmpC assay included the AmpC genes MOX, FOX, EBC, CIT, ACC and DHA, along with a 16S rDNA 110 control. Primers used in each reaction were analysed in all combinations by BLAST to screen for 111 unintended products, and dimer potential was analysed using Multiple Primer Analyzer (ThermoFisher, 112 US). 113
HRM assays 114
The ESBL/Carb HRM assay includes 9 primer pairs, and the AmpC assay contains 7 primer pairs including 115 an internal control primer set. Amplicon context sequences are provided in accordance with MIQE 116 guidelines 39 , in supplementary table 2. 117
Each HRM reaction contained 12.5 µl Type-it® HRM buffer (Qiagen, UK), primers, and molecular grade 118 water added to a final volume of 20 µl. A 5µl volume of the DNA sample was then added. The qPCR-HRM 119 protocol consisted of an initial denaturation step at 95°C for 5 minutes, followed by 40 cycles of; DNA 120 denaturation at 95°C for 10 seconds, primer annealing at 58°C for 30 seconds, and primer extension at 121 72°C for 10 seconds with fluorescence monitored in the FAM channel. HRM analysis was carried out 122 over a temperature range of 75°C to 90°C, increased in 0.1°C increments. The results were analysed 123 using the Rotor-Gene Q Software. 124
The HRM assays were developed using DNA extracted from single isolates in the collection possessing 125 one of the target genes. Due to difficulty in sourcing isolates possessing MOX or ACC genes, plasmids 126 containing the sequences for each gene accessed from GenBank (Accession numbers D13304.2 and 127 the ESBL/Carb assay was set from these initial experiments as 0.4 dF/dT (10% max dF/dT obtained) and 129 retained for all future experiments. The threshold of the AmpC assay was increased to 0.63 to avoid the 130 greater background signal. The amplicon melt temperatures for automatic result calling for each gene 131 are given in Supplementary Table 1 , and +/-0.5C was set as the calling range, except for 16S which was 132 +/-1C. Due to sequence variation in the CTX-M genes, CTX-M groups one, two and eight have one peak 133 temperature range (denoted group 1), and groups 9 and 25 have another (group 9). 134 DNA was stored at -20 o C prior to use. 149
HRM assay evaluation
Molecular characterization 150
All isolates were characterized for ESBL, AmpC and carbapenemase genes using reference assays 151 detailed in 28 , 42 and 32 , respectively, with some modifications. All thermal cycling parameters were as 152 previously described, DreamTaq PCR reaction mix (Thermo Fisher Scientific, UK) was used for all assays 153 and PCR was performed in the Rotor-Gene Q (Qiagen, UK). Reaction products were analyzed by gel 154 electrophoresis (1% agarose) to confirm expected product size, and select amplicons were bi 155 directionally Sanger sequenced commercially (Source Bioscience, UK) after purification with a QIAQuick 156 PCR purification kit (Qiagen, UK). Reactions were carried out in triplicate, and one or more positive 157 reactions was interpreted as a positive result 158
Assay evaluation 159
The extracted DNA from all 111 characterised isolates was tested once with the HRM assays, including 160 the isolates used during the assay development due to the expected low numbers of certain genotypes. 161
In accordance with STARD guidelines 43 the HRM assay was carried out by an operator blinded to the 162 reference test results, with positivity called automatically by the RGQ software. The results were then 163 compared against the reference standard PCR and sequencing to estimate diagnostic accuracy. 164
Intra assay variation 165
A strain harboring each AMR gene was selected, and the extracted DNA samples were tested in six 166 replicate reactions in a single qPCR run. These results were used to calculate the intra assay variation for 167 each target peak. 168
Results 169
HRM assays 170
The ESBL/Carbapenemase (ESBL/Carb) HRM assay was able to detect all eight targets, producing a 171 distinct peak for each ( Fig.1.A) . The mean Tm difference between each peak was 1.5 o C (range: 1.9 o C -1.1 o C), and the minimum difference over 1 o C as designed to facilitate differentiation. The AmpC assay 173 generated distinct peaks for each target gene, accompanied by a 16S rRNA control peak in each isolate, 174 apart from the MOX and ACC genes which were synthesised as plasmids ( Fig.1.B) . The average Tm 175 difference was 1.55 o C (range: 1.15 o -2 o C). No spurious or unexpected peaks were obtained. 176
HRM assay evaluation 177
The assays were evaluated on 111 Gram-negative isolates with mixed resistance patterns. In 178 combination, the two assays correctly identified 97/99 (sensitivity 98%, CI: 92.8%-99.8%) isolates as 179 carrying at least one resistance marker (Table 1. ). The sensitivity of the assays for carbapenemase, ESBL 180 and AmpC genes was 96.7% (CI: 82.8-99.9%), 93.6% (CI: 85.7-97.9%) and 93.8% (CI: 82.8-98.7%), 181
respectively. The specificity of the tests for the same genes were 100% (CI: 95.6-100%), 93.9% (CI: 79.8-182 99.3%) and 93.7% (CI: 84.5-98.2%). 183
Compared with phenotypic disk diffusion based testing, the HRM assays were 96.7% (CI: 82.8%-99.9%) 184 sensitive and 100% (CI: 95.5%-100.0%) specific for the detection of carbapenemase resistance. The assay 185 was 88% sensitive (CI: 78.7%-94.4%) and 94% specific (CI: 80.3% to 99.3%) for detecting 3 rd generation 186 cephalosporin resistance (ESBL or AmpC production) in the carbapenem susceptible strains. Of the 187 ESBL/AmpC false negative samples, six were AmpC producers negative for all target genes by reference 188 PCR, and therefore potentially resistant via overexpression of a chromosomal AmpC 44 . 189
The ESBL/Carb assay could detect up to three genes simultaneously, including those with neighbouring 190 peaks (Fig.2.A-C) . Sensitivity for the particular genes targeted by the ESBL/Carb assay ranged between 191 90.6 -100%, with the exception of SHV which was 61.8% (CI: 43.6 -77.8%) (Table 1) . SHV genes were 192 often found in isolates with multiple target genes, and the sensitivity was lower for detecting all genes in 193 co-producers in comparison with isolates with a single gene. Sensitivity in carriers of one, two, three or 194 four genes was 100%, 85.2%, 86.3% and 66.7%, respectively.
The ESBL/Carb assay identified 29/30 carbapenemase producers, failing to identify a single OXA-48 196 gene. A total of 67/69 isolates (97.1%) were correctly identified as carbapenemase negative but having 197 either ESBL or AmpC genes. There were four false positive results for CTX-M (2) TEM (1) and SHV (1) 198 genes. Sequencing revealed the presence of the intended sequence in all four samples, indicating these 199 samples may have been misidentified by the reference assay. 200
The AmpC assay identified all AmpC genes with 100% (CI:86.8%-100.0%) sensitivity and specificity, with 201 the exception of EBC genes, which were detected with sensitivity and specificity of 87.5% (CI: 67.6%-202 97.3%) and 95.4% (88.6%-98.7%) respectively. The 16S control failed in 24/111 isolates. The 203 concentration of the 16S control primers is deliberately lower than the AMR gene detection sets, to 204 make sure it does not outcompete them in the reaction, and this can lead to false-negative results in 205 isolates with multiple beta-lactamase genes. 206
The Tm of target genes in both assays all fell within distinct ranges without overlaps (Fig. 3) The intra assay variation for a single producer of each target peak varied between 0.02% and 0.09% in 215 the ESBL/Carb assay, and 0.01% and 0.09% in the AmpC assay (Table 2) , indicating a high level of 216 reproducibility between replicates. 217
Discussion 218
This is the first assay that combines all major ESBL, AmpC and carbapenemase genes into a two-tube 219 assay, enabling the simultaneous detection of 14 of the most important markers of resistance to 3 rd 220 generation cephalosporins and carbapenems. Carbapenemase carriage is increasing worldwide, and 221 carriers are typically multidrug resistant, limiting the treatment options and often involving polymyxins 222 or tigecycline 45 . Resistance to these latter drugs however is also emerging 46 . Prompt diagnosis would 223 enable the rapid modification of treatment and the instigation of infection control measures to prevent 224 hospital wide outbreaks 47 . 225
The ability to simultaneously detect markers of AMR would enable the detection of ESBL and AmpC co-226 production, which are difficult to detect phenotypically and able to confer resistance to a wider range of 227 antimicrobials including inhibitor/beta-lactam combinations such as amoxicillin/clavulanic acid 48 . 228
Screening for multiple genes in this fashion is also useful for surveillance and outbreak monitoring, and 229
gives this test potential utility as an epidemiological tool. The lack of requirement for expensive 230 fluorescent hydrolysis probes, makes HRM a far cheaper way of multiplexing, with an oligonucleotide 231 cost of 3.3% that of a 15 target probe based assay, enabling the detection of a wide range of resistance 232 markers without the costs of sequencing or large qPCR panels. 233
The assay had high sensitivity of 98% for detecting isolates with any beta-lactamase gene, which is equal 234 to other molecular assays 26 . There were eight instances across the 111 isolates of genes being identified 235 by the HRM assay that were not identified by the reference standard. The reference tests used were 236 well characterized standard PCRs relying on gel based detection, which can be less sensitive than real-237 time methods 49 and therefore it is possible that these were truly positive isolates. The specificity of 238 HRM assays are typically very high, as they rely on both the specificity of the primer pairs, and the melt 239 temperature of the amplicon generated. 240
The sensitivity of the test for detecting SHV genes was lower than expected (61%), although the majority 241 of false negative SHV results occurred in isolates with multiple genes. Of the false negative SHV results 242 all the isolates were detected as either ESBL (9/13) or carbapenemase producers (4/13) via different 243 genes and therefore the resistance determination was not affected by not detecting SHV. Whilst co-244 production of ESBL genes does not affect the susceptibility phenotype of the isolate, and would not 245 impact clinical management of an infection, the ability of the assay to accurately genotype co-producers 246 would be important for its use in surveillance and for improving epidemiological data. Two of the three 247 EBC producers not identified by the assay were E. cloacae strains, and the reference PCR may have 248 amplified the chromosomal E. cloacae AmpC, which is the ancestor of ACT-1 in the EBC group 42 . The 249 HRM assay was designed solely using sequence data from plasmid mediated EBC genes, which may 250 explain why it did not successfully identify these targets. 251
The assay was developed on the Rotor-Gene, but should be transferrable to qPCR platforms designed 252 for HRM, and early experiments on the Magnetic induction cycler (Bio Molecular Systems, Australia) and 253 CFX384 (Bio-Rad, US) have shown equivalent performance. 254 This initial evaluation was performed using a panel of well characterised and mostly MDR isolates, to 255 ensure a good coverage of target genes. Further evaluations on prospectively collected isolates are 256 required to assess the assay more accurately, including the calculation of predictive values. 257
The assay detects 14 major carbapenemase, ESBL and plasmid mediated AmpC gene families with 258 sensitivity comparable to other molecular tests, within 3 hours. The assay is highly multiplexed, enabling 259 the comprehensive screening of important beta-lactamases in only two qPCR reactions, which has the 260 potential to save time and costs during testing for these markers. This assay could be used as a cost-261 effective way to determine the genetic epidemiology of local antimicrobial resistance, or used to 262 provide faster information on antimicrobial resistance from primary cultures than standard phenotypic 263 methods. 264
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The study was funded through the MRC Confidence in Concept award number MC_PC_15040. The 271 funders had no role in the design of the study, data collection, analysis or preparation of the manuscript. isolates in (B) have generated an AmpC peak in addition to a 16S rRNA peak. Two peaks are present in the TEM, CTX-M G1 and SHV bins due to the co-production of these enzymes in isolates used as example carbapenemase producers. 
